Table 3. Univariate and multivariable analysis for recurrence-free survival of patients with or without splenomegaly before PSM.

Clinical variable	Univariate analysis				Multivariate analysis
	β	HR (95% CI)	P		β	HR (95% CI)	P
Age, year	‒2.071	0.991 (0.983–1)	0.038		0.813	1.004 (0.995–1.013)	0.416
Sex, male vs. female	0.654	1.096 (0.833–1.44)	0.513
HBsAg	‒0.576	0.926 (0.713–1.203)	0.565
TBIL	0.201	1.001 (0.99–1.012)	0.841
DBIL	0.222	1.002 (0.985–1.02)	0.824
ALB	‒0.623	0.994 (0.974–1.014)	0.533
ALT	0.34	1 (0.999–1.002)	0.734
PT	‒0.453	0.998 (0.991–1.005)	0.65
AFP	3.273	1 (1.0–1.0)	0.001		0.108	1 (1.0–1.0)	0.914
Tumor diameter	2.425	1.022 (1.004–1.04)	0.015		1.554	1.017 (0.995–1.04)	0.12
Esophageal and gastric varices	0.851	1.093 (0.891–1.341)	0.395
Ascites	‒0.644	0.92 (0.713–1.186)	0.52
Liver cirrhosis	2.3	1.232 (1.031–1.472)	0.021		‒1.633	0.851 (0.701–1.033)	0.102
No# of tumor	‒1.171	0.867 (0.682–1.101)	0.242
PVTT	3.353	1.346 (1.131–1.601)	0.001		‒0.144	0.986 (0.809–1.2)	0.885
Tumor capsule	‒6.057	0.753 (0.687–0.825)	<0.001		‒5.157	0.283 (0.175–0.457)	<0.001
CA199	0.4	1 (0.999–1.002)	0.689
CEA	0.85	1.008 (0.989–1.027)	0.396
AST	4.18	1.004 (1.002–1.006)	<0.001		3.818	1.004 (1.002–1.006)	<0.001
Thickness of splenic hilum	4.595	1.185 (1.102–1.275)	<0.001		2.739	1.117 (1.032–1.209)	0.006
PLT	1.445	1.001 (1–1.002)	0.149

PSM, propensity score matching; HBsAg, Hepatitis B surface antigen; TBIL, Total Bilirubin; DBIL, Direct Bilirubin; ALB, Albumin; ALT, Alanine Aminotransferase; PT, Prothrombin time; AFP, α-fetoprotein; PVTT, portal vein tumor thrombus; CA199, Carbohydrate Atigen 19-9; CEA, Carcinoembryonic antigen; AST, Aspartate Aminotransferase; PLT, Platelet.